FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes
Summary
The FDA has warned telehealth companies about promoting unofficial weight loss drugs without approval. Companies like Hims & Hers are asked to stop using misleading advertising for drugs that imitate prescription weight loss injections.Key Facts
- The FDA is targeting telehealth companies for advertising unofficial versions of prescription drugs.
- This action is part of efforts to regulate pharmaceutical advertising.
- Over 100 letters were sent to drugmakers and online prescribing companies.
- Hims & Hers is a company named in the FDA's actions.
- Hims & Hers promotes less expensive versions of popular obesity injections.
- The FDA says these versions claim to use the same active ingredients as approved drugs like Wegovy and Ozempic.
- The drugs in question come from specialty compounding pharmacies, which the FDA does not review.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.